Patents by Inventor Matthew D. Neal

Matthew D. Neal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11918331
    Abstract: A movement detection device includes a signal transmission device configured to transmit a radar signal transmission toward a target area and to receive reflected radar signals, and a signal analysis device configured to analyze the reflected radar signals to detect a movement in the target area that is indicative of micro-shivering. In response to detecting the micro-shivering, the movement detection device generates an alarm.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: March 5, 2024
    Assignee: Hill-Rom Services, Inc.
    Inventors: Steven D. Baker, Jennifer Bergstrom, Heinz-Hermann Dalbert, Brandon P. Fisk, Yongji Fu, Michael S. Hood, Charles A. Lachenbruch, John A. Lane, Kenzi L. Mudge, Matthew O'Neal, Frank E. Sauser, Douglas A. Seim, Gregory J. Shannon
  • Publication number: 20210308162
    Abstract: The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
    Type: Application
    Filed: February 11, 2021
    Publication date: October 7, 2021
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Peter Wipf, Matthew D. Neal, Chhinder P. Sodhi, David J. Hackam
  • Patent number: 10933077
    Abstract: The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: March 2, 2021
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Peter Wipf, Matthew D. Neal, Chhinder P. Sodhi, David J. Hackam
  • Publication number: 20190374562
    Abstract: The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
    Type: Application
    Filed: April 17, 2019
    Publication date: December 12, 2019
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Peter Wipf, Matthew D. Neal, Sodhi P. Chhinder, David J. Hackam
  • Patent number: 10300083
    Abstract: The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: May 28, 2019
    Assignee: University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Peter Wipf, Matthew D. Neal, Sodhi P. Chhinder, David J. Hackam
  • Publication number: 20170095493
    Abstract: The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
    Type: Application
    Filed: December 19, 2016
    Publication date: April 6, 2017
    Applicant: University of Pittsburgh - of the Commonwealth System of Higher Education
    Inventors: Peter Wipf, Matthew D. Neal, Sodhi P. Chhinder, David J. Hackam
  • Patent number: 9532999
    Abstract: The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: January 3, 2017
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Peter Wipf, Matthew D. Neal, Sodhi P. Chhinder, David J. Hackam
  • Publication number: 20150250809
    Abstract: The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
    Type: Application
    Filed: May 20, 2015
    Publication date: September 10, 2015
    Applicant: University of Pittsburgh - of the Commonwealth System of Higher Education
    Inventors: Peter Wipf, Matthew D. Neal, Sodhi P. Chhinder, David J. Hackam
  • Patent number: 9072760
    Abstract: The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: July 7, 2015
    Assignee: University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Peter Wipf, Matthew D. Neal, Sodhi P. Chhinder, David J. Hackam